BioNTech SE

BNTX

US09075V1026

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
90.13 ^USD	-0.83%		+0.20%	-14.60%

May. 08	HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	MT
May. 08	BIONTECH : Deutsche Bank reaffirms its Neutral rating	ZD

BIONTECH : JP Morgan remains Neutral

November 10, 2020 at 04:39 pm EST

In a research note, JP Morgan analyst Cory Kasimov has maintained his recommendation on the stock with a Neutral rating. The target price has been raised to USD 90 from USD 68.

Latest news about BioNTech SE

HC Wainwright Raises BioNTech SE Price Target to $113 From $107, Maintains Buy Rating	May. 08	MT
BIONTECH : Deutsche Bank reaffirms its Neutral rating	May. 08	ZD
TD Cowen Adjusts BioNTech Price Target to $98 From $95, Maintains Hold Rating	May. 07	MT
BMO Capital Adjusts BioNTech Price Target to $122 From $123, Maintains Outperform Rating	May. 07	MT
Bank Stocks Lead European Equities Traded in the US as American Depositary Receipts Higher Tuesday	May. 07	MT
BIONTECH : Goldman Sachs reiterates its Neutral rating	May. 07	ZD
Sector Update: Health Care Stocks Higher in Late Afternoon Trading	May. 06	MT
Sector Update: Health Care Stocks Advance in Monday Afternoon Trading	May. 06	MT
Sector Update: Health Care	May. 06	MT
BIONTECH : Jefferies gives a Neutral rating	May. 06	ZD
Top Midday Stories: Tyson Shares Tumble on Earnings Miss; Robinhood Receives Wells Notice From SEC Staff; Spirit Airlines to Furlough up to 260 Pilots; Shell in Talks to Sell Malaysian Gas Station Business to Saudi Aramco	May. 06	MT
BioNTech Swings to First-Quarter Loss as Lower COVID-19 Commercial Sales Dents Topline	May. 06	MT
Dpa-AFX Overview: COMPANIES from 06.05.2024 - 15:15	May. 06	DP
Sector Update: Health Care Stocks Gain Pre-Bell Monday	May. 06	MT
Sector Update: Health Care	May. 06	MT
Transcript : BioNTech SE, Q1 2024 Earnings Call, May 06, 2024	May. 06
BioNTech Swings to Net Loss on Lower Covid Vaccine Sales	May. 06	DJ
BioNTech Swings to Q1 Loss, Revenue Falls -- Shares Decline Pre-Bell	May. 06	MT
Futures Rise Pre-Bell Ahead of Latest Earnings Week; Asia Mostly Up, Europe Strong	May. 06	MT
Inflation, Interest Rate Outlooks Lift Wall Street Pre-Bell; Asia, Europe Up	May. 06	MT
BioNTech says 90% of 2024 revenues will accrue at end of year	May. 06	RE
BioNTech SE Reiterates Revenue Guidance for the Full Year 2024	May. 06	CI
BioNTech SE Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 06	CI
North American Morning Briefing : Stock Futures Rise as Hopes of Rate Cut Return	May. 06	DJ
News Highlights : Top Global Markets News of the Day - Monday at 5 AM ET	May. 06	DJ

BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.

Sector

Biotechnology & Medical Research

Calendar

2024-05-17 - Annual General Meeting

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

BIONTECH : A miss is a miss

March 21, 2024 at 09:27 am EDT

More Strategies

Ratings for BioNTech SE

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

83.87 EUR

Average target price

106.9 EUR

Spread / Average Target

+27.44%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
BIONTECH SE	-14.60%	21.72B
VERTEX PHARMACEUTICALS INCORPORATED	+2.93%	108B
ARGENX SE	-1.02%	23.46B
GENMAB A/S	-7.05%	18.64B
WUXI APPTEC CO., LTD.	-38.55%	17.45B
BEIGENE, LTD.	-8.83%	17.19B
NEUROCRINE BIOSCIENCES, INC.	+5.51%	13.99B
SAREPTA THERAPEUTICS, INC.	+37.49%	12.53B
VIKING THERAPEUTICS, INC.	+329.39%	8.81B
LEGEND BIOTECH CORPORATION	-24.02%	8.32B

Bio Therapeutic Drugs

BioNTech SE

Equities

BNTX

US09075V1026

Biotechnology & Medical Research

BIONTECH : JP Morgan remains Neutral

Latest news about BioNTech SE

Chart BioNTech SE

Company Profile

Income Statement Evolution

Analysis / Opinion

Ratings for BioNTech SE

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs